XILIO THERAPEUTICS, INC.

Consensus Xilio Therapeutics, Inc.

Stocks

XLO

US98422T2096

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 24/09/2026 +03			5-day change	1st Jan Change
9.000 ^USD	+0.67%		-0.44%	+0.42%

08-12	Xilio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index	CI

Evolution of the Average Target: Xilio Therapeutics, Inc.

Evolution of the Target Price: Xilio Therapeutics, Inc.

Changes in Analyst Recommendations: Xilio Therapeutics, Inc.

ea412b923acd8555492.cur1tyZvYYQvTn-Ni2vht9oCGBGBOusUOzzffnMAeDo.F4aYj05bL8kaeBTv6CGswZ1nd07lYKxmTXaPFh5pN10gjbP-UwIvz00MGA~a9af5390f4de8f8de7e09c370f6629f4

Analysts' recommendations: Xilio Therapeutics, Inc.

06/08/25	Leerink Partners Initiates Xilio Therapeutics at Outperform With $2 Price Target	MT
27/01/23	Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $10 From $20, Maintains Overweight Rating	MT
21/12/22	Chardan Initiates Xilio Therapeutics With Buy Rating, $7 Price Target	MT
10/11/22	Raymond James Adjusts Price Target on Xilio Therapeutics to $13 From $31, Maintains Outperform Rating	MT
10/08/22	Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $20 From $32, Reiterates Overweight Rating	MT
10/01/22	HC Wainwright Starts Xilio Therapeutics at Buy with $36 Price Target	MT
16/11/21	Guggenheim Starts Xilio Therapeutics at Buy With $40 Price Target	MT
16/11/21	Raymond James Starts Xilio Therapeutics at Outperform With $31 Price Target	MT
16/11/21	Morgan Stanley Starts Xilio Therapeutics at Overweight With $32 Price Target	MT
16/11/21	Cowen Starts Xilio Therapeutics at Outperform	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	XILIO THERAPEUTICS, INC.			-	-	+122.22%
	LONZA GROUP AG					+20.73%
	IQVIA HOLDINGS INC.					+1.06%
	BEONE MEDICINES AG					+20.23%
	REVOLUTION MEDICINES, INC.					+27.05%
	CELLTRION, INC.					+50.95%
	MEDPACE HOLDINGS, INC.					-6.25%
	EUROFINS SCIENTIFIC SE					-7.05%
	ASCENDIS PHARMA A/S					+35.3%
	TEMPUS AI, INC.					-16.64%
	Average					+24.76%
	Weighted average by Cap.					+17.14%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

9.000USD

Average target price

20.00USD

Spread / Average Target

+122.22%

High Price Target

20.00USD

Spread / Highest target

+122.22%

Low Price Target

20.00USD

Spread / Lowest Target

+122.22%

Analyst Consensus Detail

Consensus revision (last 18 months)

Stock Market
Stocks
XLO Stock
Consensus Xilio Therapeutics, Inc.

As early as today, start finding the best investment opportunities!